Alembic Pharmaceuticals Ltd banner

Alembic Pharmaceuticals Ltd
NSE:APLLTD

Watchlist Manager
Alembic Pharmaceuticals Ltd Logo
Alembic Pharmaceuticals Ltd
NSE:APLLTD
Watchlist
Price: 764.7 INR 0.7% Market Closed
Market Cap: ₹150.3B

P/E

23.9
Current
22%
Cheaper
vs 3-y average of 30.7

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
23.9
=
Market Cap
₹144.7B
/
Net Income
₹6.3B

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
23.9
=
Market Cap
₹144.7B
/
Net Income
₹6.3B

Valuation Scenarios

Alembic Pharmaceuticals Ltd is trading below its 3-year average

If P/E returns to its 3-Year Average (30.7), the stock would be worth ₹981.67 (28% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+28%
Average Upside
24%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 23.9 ₹764.7
0%
3-Year Average 30.7 ₹981.67
+28%
5-Year Average 28.8 ₹922.9
+21%
Industry Average 30.4 ₹971.32
+27%
Country Average 28.7 ₹918.48
+20%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
₹144.7B
/
Jan 2026
₹6.3B
=
23.9
Current
₹144.7B
/
Mar 2026
₹6.9B
=
21
Forward
₹144.7B
/
Mar 2027
₹8.5B
=
17.1
Forward
₹144.7B
/
Mar 2028
₹10.2B
=
14.2
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Peer Comparison

Market Distribution

In line with most companies in India
Percentile
41st
Based on 3 123 companies
41st percentile
23.9
Low
0 — 18.9
Typical Range
18.9 — 44.4
High
44.4 —
Distribution Statistics
India
Min 0
30th Percentile 18.9
Median 28.7
70th Percentile 44.4
Max 877 228.1

Alembic Pharmaceuticals Ltd
Glance View

Market Cap
150.3B INR
Industry
Pharmaceuticals

Alembic Pharmaceuticals Ltd., with roots tracing back over a hundred years, began as a modest tincture and alcohol company in Vadodara, India. Its journey from crafting everyday remedies to becoming a stalwart in the pharmaceutical industry exemplifies ambition intertwined with tradition. Today, Alembic stands as a formidable entity, specializing in the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs) and generic formulations. The company thrives on a blend of innovation and scalability, strategically advancing its manufacturing capabilities while adhering to stringent quality standards. This commitment has not only bolstered its domestic stronghold but also enabled it to penetrate highly regulated international markets, such as the United States and Europe. The company's revenue model is anchored on an extensive portfolio that addresses therapeutic areas ranging from cardiovascular and anti-diabetics to respiratory and anti-infective products. By leveraging its robust R&D infrastructure, Alembic consistently introduces new and complex generics, amplifying its offerings while navigating the generic drug pricing pressures. Their vertically integrated operations ensure cost efficiency and control over API supplies, easing supply chain constraints and fortifying their competitive position. Additionally, strategic partnerships and investments in advanced manufacturing technologies have augmented its capability to meet global demands, cementing Alembic’s reputation as a reliable partner in the pharmaceutical landscape. This multifaceted approach not only expands its business horizons but firmly establishes Alembic as a key player in addressing global healthcare needs.

APLLTD Intrinsic Value
861.77 INR
Undervaluation 11%
Intrinsic Value
Price ₹764.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett